Kavar Capital Partners Group LLC Sells 460 Shares of GSK plc (NYSE:GSK)

Kavar Capital Partners Group LLC decreased its holdings in shares of GSK plc (NYSE:GSK) by 1.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 32,472 shares of the pharmaceutical company’s stock after selling 460 shares during the period. Kavar Capital Partners Group LLC’s holdings in GSK were worth $1,327,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. JTC Employer Solutions Trustee Ltd grew its holdings in shares of GSK by 71.3% during the first quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock valued at $909,063,000 after buying an additional 8,800,822 shares during the last quarter. Primecap Management Co. CA grew its holdings in shares of GSK by 13.9% during the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after buying an additional 1,773,020 shares during the last quarter. Mondrian Investment Partners LTD grew its holdings in shares of GSK by 37.8% during the first quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock valued at $236,250,000 after buying an additional 1,512,442 shares during the last quarter. Equity Investment Corp grew its holdings in shares of GSK by 1.0% during the second quarter. Equity Investment Corp now owns 3,433,202 shares of the pharmaceutical company’s stock valued at $132,178,000 after buying an additional 34,631 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of GSK by 30.9% during the second quarter. Renaissance Technologies LLC now owns 2,347,993 shares of the pharmaceutical company’s stock valued at $90,398,000 after buying an additional 554,600 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on GSK. Argus upgraded shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Finally, Jefferies Financial Group raised their target price on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Four research analysts have rated the stock with a hold rating, two have given a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $50.00.

Insider Transactions at GSK

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

GSK Trading Down 0.6 %

Shares of GSK stock opened at $37.52 on Friday. The firm’s 50 day moving average is $41.12 and its 200 day moving average is $41.14. The stock has a market capitalization of $77.76 billion, a P/E ratio of 15.13, a P/E/G ratio of 1.23 and a beta of 0.65. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.92. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.99.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.09. The business had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. GSK had a net margin of 12.87% and a return on equity of 51.48%. Research analysts expect that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were paid a dividend of $0.3843 per share. This represents a $1.54 annualized dividend and a dividend yield of 4.10%. The ex-dividend date of this dividend was Friday, August 16th. This is a boost from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is currently 62.10%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.